Acute chemical toxicity of uranium

Health Physics

Volumn 94, Issue 2, 2008, Pages 170-179

  Kathren, Ronald L ^a,c   Burklin, Richard K ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b AREVA NP   (France)

^c NONE   (United States)

Author keywords

Ingestion; Inhalation; Injection; Uranium

Indexed keywords

BENZODIAZEPINE; BICARBONATE; EDETATE CALCIUM; PENTETATE CALCIUM; URANIUM; URANYL NITRATE;

ACUTE TOXICITY; ALBUMINURIA; ARTICLE; CHELATION THERAPY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOSE CALCULATION; FANCONI RENOTUBULAR SYNDROME; GLUCOSURIA; HUMAN; INGESTION; INHALATION; INJECTION; KIDNEY FUNCTION; LD 50; LUNG FUNCTION; LUNG TOXICITY; NEPHROTOXICITY; NONHUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REFERENCE VALUE; SIDE EFFECT; SOLUBILITY; URINARY EXCRETION;

ANIMALS; DIABETES MELLITUS; ENVIRONMENTAL EXPOSURE; HUMANS; KIDNEY; LETHAL DOSE 50; MAMMALS; RADIATION MONITORING; URANIUM; URANIUM COMPOUNDS;

ANIMALIA; CAVIA; MAMMALIA; RATTUS;

EID: 38049148369     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HP.0000288043.94908.1f     Document Type: Article

References (48)

1. Agency for Toxic Substances and Disease Registry. Toxicological profile for uranium (update). Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service; 1999.
2. Alexander RE. Biokinetics model for uranium inhalation/excretion, uranium mill workers. In: Moore RH, ed. Biokinetics and analysis of uranium in man. Richland, WA: United States Uranium Registry; Report USUR-05, HEHF-47; 1984.
3. Athey GF, McGuire SA, Van Ramsdell J Jr. RASCAL 3.0.5 workbook. Washington, DC: U.S. Nuclear Regulatory Commission; 2007.
4. Bailey M, Davis K. The health hazards of depleted uranium munitions, Part II. Annexe A: Estimations of kidney uranium concentrations from published reports of uranium intakes in humans. London: The Royal Society; 2002.
5. Bassett SH, Frenkel A, Cedars N, Van Alstine H, Waterhouse C, Cusson K. The excretion of hexavalent uranium following intravenous administration. II. Studies on human subjects. Washington, DC: U.S. Atomic Energy Commission; Report UR-37, University of Rochester Atomic Energy Project; 1948.
6. Bond CH. Remarks upon the value of uranium nitrate in the control of glycosuria. The Practitioner Vol. viii:257-264; September 1898.
7. Bradbury JB. Case of diabetes mellitus treated by uranium nitrate. Brit Med J II:847; 1896.
8. Brodsky A. Review of radiation risks and uranium toxicity. Hebron, CT: RSA Publications; 1996.
9. Butterworth A. The significance and value of uranium in urine analysis. Trans Assoc Industrial Med Officers 5:36-43; 1955.
10. Dang HS, Pullat VR, Pillai KC. Gastrointestinal absorption factor for uranium incorporated in diet. Radiat Protect Dosim 40:195-197; 1992.
11. Duncan E. The treatment of diabetes mellitus by nitrate of uranium. Brit Med J II:1044 -1047; 1897.
12. Durbin PW, Wrenn ME. Metabolism and effects of uranium in animals. In: Conference on Occupational Health Experience with Uranium, Arlington, Virginia, 28-30 April 1975. Washington, DC: U.S. Energy Research and Development; Administration Report ERDA-93; 1975: 67-129.
13. Fisher DR, Swint MJ, Kathren RL. Evaluation of health effects in Sequoyah Fuels Corporation (SFC) workers from accidental exposure to uranium hexafluoride. Washington, DC: U.S Nuclear Regulatory Commission/Pacific Northwest Laboratory; Report NUREG/CR-5566 (PNL-7328); 1990.
14. Fulco CE, Liverman CT, Sox HC. Gulf War and health. Volume 1. Depleted uranium, pyridostigmine bromide, sarin, and vaccines. Washington, DC: Institute of Medicine, National Academies Press; 2000.
15. Harduin JC, Royer Ph, Piechowski J. Uptake and urinary excretion of uranium after oral administration in man. Radiat Protect Dosim 53:245-248; 1994.
16. Harris WB. Experimental clearance of uranium dust from the human body. In: Davies CN, ed. Inhaled particles and vapours. Proceedings of an International Symposium held in Oxford, 29 March-1 April 1960. London: Pergamon Press; 1961: 209-215.
17. Hodge HC. A history of uranium poisoning (1824 -1942). In: Hodge HC, Stannard JN, Hursh JB, eds. Uranium plutonium transplutonic elements. Handbook of experimental pharmacology XXXVI. New York: Springer-Verlag; 1973: 5-68.
18. Hursh JB, Spoor NH. Data on man. In: Hodge HC, Stannard JN, Hursh JB, eds. Uranium plutonium transplutonic elements. Handbook of experimental pharmacology XXXVI. New York: Springer-Verlag; 1973: 197-239.
19. International Commission on Radiological Protection. Report of Committee IV on evaluation of radiation doses to body tissues from internal contamination due to occupational exposure. Oxford: Pergamon Press; ICRP Publication 10; 1968.
20. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. Oxford: Pergamon Press; ICRP Publication 30, Annals of the ICRP 2(3/4); 1979.
21. International Commission on Radiological Protection. Human respiratory tract model for radiation protection. Oxford: Pergamon Press; ICRP Publication 66, Annals of the ICRP 24(1-3); 1994a.
22. International Commission on Radiological Protection. Dose coefficients for intakes of radionuclides by workers. Oxford: Pergamon Press; ICRP Publication 68, Annals of the ICRP 24(4); 1994b.
23. International Commission on Radiological Protection. Age-dependent doses to members of the public from intake of radionuclides: Part 5, compilation of ingestion and inhalation dose coefficients. Oxford: Pergamon Press; ICRP Publication 72, Annals of the ICRP 26(1); 1996.
24. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis 41:292-309; 2003.
25. James AC. User manual for IMBA-URAN, Framatone ANP Edition (Version 3.0). Richland, WA: ACJ and Associates, Inc.; 2002.
26. Just RA. Report of toxicological studies concerning exposures to UF6 and UF6 hydrolosis products. Oak Ridge, TN: U.S. Department of Energy Oak Ridge Gaseous Diffusion Plant; Report K/D-5573, Revision 1, Martin Marietta Energy Systems; 1984.
27. Just RA, Emler VS. Generic report on health effects for U.S. gaseous diffusion plants. Oak Ridge, TN: U.S. Department of Energy Oak Ridge Gaseous Diffusion Plant; Report K/D-5050-Sect. 8-Pt. 1, Martin Marietta Energy Systems; 1984.
28. Kathren RL, Moore RH. Acute accidental inhalation of U: a 38 year follow up. Health Phys 51:609-619; 1986.
29. Kathren RL, Weber JL. Ultrasensitive techniques for measurement of uranium in biological samples and the nephrotoxicity of uranium. Proceedings of a public meeting in Washington, DC, 4-5 December 1985. Washington, DC: U.S. Nuclear Regulatory Commission; Report NUREG/CP-0093; 1988.
30. Leggett RW. The behavior and chemical toxicity of U in the kidney: a reassessment. Health Phys 57:365-384; 1989.
31. Leussenhop AJ, Gallimore JC, Sweet WH, Struxness EG, Robinson J. The toxicity in man of hexavalent uranium following intravenous injection. Am J Roentgenol Radium Ther Nucl Med 79:83-100; 1958.
32. Limson Zamora M, Zielinski JM, Meyerhof DP, Tracy BL. Gastrointestinal absorption of uranium in humans. Health Phys 83:35- 45; 2002.
33. Maynard EA, Hodge HC. Oral toxicity of uranium compounds. In: Voegtlin C, Hodge C, eds. Pharmacology and toxicology of uranium compounds. National Nuclear Energy Series VI. New York: McGraw-Hill Book Company; 1949: 309-376.
34. McGuire SA. Chemical toxicity of uranium hexafluoride compared to acute effects of radiation. Washington, DC: U.S. Nuclear Regulatory Commission; Report NUREG-1391; 1991.
35. Medley DW, Kathren RL, Miller AG. Diurnal urinary volume and uranium output in uranium workers and unexposed controls. Health Phys 67:122-130; 1994.
36. 2 in dogs. Health Phys 43:859-873; 1982.
37. Orcutt JA. The toxicology of compounds of uranium following application to the skin. In: Voegtlin C, Hodge HC. Pharmacology and toxicology of uranium compounds. National Nuclear Energy Series VI. New York: McGraw-Hill Book Company; 1949: 377-414.
38. Pavlakis N, Pollock CA, McLean G, Bartrop AR. Deliberate overdose of uranium. Nephron 72:313-317; 1996.
39. Spoor NL, Hursh JB. Protection criteria. In: Hodge HC, Stannard JN, Hursh JB, eds. Uranium plutonium transplutonic elements. Handbook of experimental pharmacology XXXVI. New York: Springer-Verlag; 1973: 241-270.
40. Stannard JN. Radioactivity and health: a history. Columbus, OH: Battelle Press; 1988.
41. Struxness EG, Leussenhop AJ, Bernard SR, Gallimore JC. The distribution and excretion of hexavalent uranium in man. In: Proceedings of the International Conference of the Peaceful Uses of Atomic Energy, Volume 10, held in Geneva, 8-20 August 1955. New York: United Nations; 1956: 186-196.
42. Tannenbaum A, Silverstone H. Factors affecting uranium poisoning. In: Tannenbaum A, ed. Toxicology of uranium. New York: McGraw-Hill; 1951: 11-15.
43. West S. The treatment of diabetes mellitus by uranium nitrate. Brit Med J II:467-472; 1895.
44. West S. Further contribution on the treatment of diabetes mellitus by uranium nitrate. Brit Med J II:729-730; 1896.
45. Wilcox RW. The theraputics of uranium nitrate. Med Rec (NY) 92:361-364; 1917.
46. Wrenn ME, Durbin PW, Howard B, Lipzstein J, Rundo J, Still ET, Willis DL. Metabolism of ingested U and Ra. Health Phys 48:601-633; 1985.
47. Yuile CL. Animal experiments. In: Hodge HC, Stannard JN, Hursh JB, eds. Uranium plutonium transplutonic elements. Handbook of Experimental Pharmacology XXXVI. New York: Springer-Verlag; 1973: 165-196.
48. Zhao S, Zhao F-Y. Nephrotoxic limit and annual limit on intake for natural U. Health Phys 58:619-623; 1990.